FDA
-
-
-
-
-
-
-
Vigil Neuroscience Inc (VIGL) PT Lowered to $14 at H.C. Wainwright
-
-
-
-
-
-
-
Mizuho Reiterates Outperform Rating on Vigil Neuroscience Inc (VIGL)
-
-
-
-
-
-
-
Vigil Neuroscience (VIGL) Reports Interim Data from Ongoing Phase 1 Clinical Trial of VG-3927
-
-
-
-
-
-
-
Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi
-
-
-
-
-
-
-
Vigil Neuroscience (VIGL) Issues 2023 Update, Highlights 2024 Milestones
-
-
-
-
-
-
-
Vigil Neuroscience Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for VGL101 for the Treatment of ALSP
-
-
-
-
-
-
-
Vigil Neuroscience Appoints Samantha Budd Haeberlein, Ph.D. to Board of Directors
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

